India Glycols rises 5% after receiving certified NCLT order for demerger

India Glycols Ltd shares were in demand on Thursday after the company said it has received the certified true copy of the National Company Law Tribunal (NCLT) order approving its long-planned demerger. The stock was last traded at Rs 1,162, up 5.0% for the session, as investors reacted to the clearer timeline for spinning off its biopharma and spirits/biofuel businesses into separate listed plays.

What India Glycols disclosed

In its 20 August 2026 filing (letter no. IGL/SE/2026-27/45), India Glycols informed the exchanges that it has now received the certified true copy of the Allahabad Bench, Prayagraj NCLT order dated 17 July 2026 sanctioning the Scheme of Arrangement among:

• India Glycols Limited (the Demerged Company)
• Ennature Bio Pharma Limited (Resulting Company 1)
• IGL Spirits Limited (Resulting Company 2)

The company noted that this is in continuation of its earlier intimation dated 20 July 2026 (no. IGL/SE/2026-27/25), where it had already disclosed that the NCLT had approved the scheme.

Crucially, the filing reiterates that:

• The Appointed Date for the scheme is 1st April, 2026.
• The Effective Date and Record Date will be determined by the boards of all three companies in line with the scheme and “shall be communicated in due course.”

This certified copy is a procedural but important step: without it, the companies cannot complete the remaining statutory filings and corporate actions needed to make the demerger effective.

How the demerger is structured

The detailed NCLT order attached to the filing (pages 2–9) lays out how the business will be split and what existing shareholders will receive once the scheme becomes effective.

1. Biopharma undertaking to Ennature Bio Pharma (Resulting Company 1)
According to page 5 of the order:

• Upon the scheme becoming effective, the Biopharma Undertaking of India Glycols, “together with all its rights, benefits, interests and obligations”, will be transferred to and vested in Ennature Bio Pharma Limited as a going concern.
• All proceedings specifically relating to the Biopharma Undertaking will continue by or against Ennature Bio Pharma.
• All employees of India Glycols “engaged in or in relation to the Biopharma Undertaking” will be deemed transferred to Ennature Bio Pharma “without any interruption of service and on the basis of continuity of service”.
• Ennature Bio Pharma will issue and allot 1 equity share of face value Rs. 5 each for every 3 equity shares of face value Rs. 5 each held in India Glycols to shareholders whose names appear on the Record Date. The existing equity shares held by India Glycols in Ennature Bio Pharma will stand cancelled when the scheme becomes effective.

2. Spirits and biofuel undertaking to IGL Spirits (Resulting Company 2)
On page 6, the order sets out a parallel structure for the spirits and biofuel business:

• The Spirits and Biofuel Undertaking of India Glycols, with all its rights, benefits, interests and obligations, will be transferred to and vested in IGL Spirits Limited as a going concern.
• All proceedings specifically relating to the Spirits and Biofuel Undertaking will continue by or against IGL Spirits.
• Employees engaged in or in relation to this undertaking will move to IGL Spirits on the same continuity-of-service basis.
• IGL Spirits will issue and allot 1 equity share of face value Rs. 5 each for every 1 equity share of face value Rs. 5 each held in India Glycols on the Record Date. Existing equity shares held by India Glycols in IGL Spirits will be cancelled once the scheme is effective.

3. Remaining business stays with India Glycols
As clarified on page 7, the Remaining Business and all related assets, liabilities and obligations will continue to belong to and be managed by India Glycols.

The order also details (pages 7–8) how licences, approvals, tax liabilities and ongoing proceedings under the Income Tax Act and other laws will be apportioned between the demerged company and the two resulting companies, and makes clear that the scheme does not grant any exemption from payment of taxes.

Why the stock moved on this filing

The market had already been told on 20 July 2026 that the NCLT had sanctioned the scheme. Thursday’s filing did not change the economics of the demerger or the swap ratios, but it did confirm a key procedural milestone: India Glycols has now received the certified true copy of the NCLT order dated 17 July 2026.

That matters because, as the order notes on page 8, the petitioner companies must deliver a certified copy of the order to the Registrar of Companies within thirty days, and regulators and other authorities are directed to act on a copy of the order annexed with the scheme (page 9). In practice, receipt of the certified order:

• Clears the way for statutory filings with the Registrar of Companies,
• Allows the boards to formally fix the Effective Date and Record Date, and
• Brings the share allotment in Ennature Bio Pharma and IGL Spirits closer to execution.

The stock’s 5.0% rise appears to reflect investors pricing in this increased certainty and the approaching timeline for value “unlock” via two focused entities — one in biopharma and one in spirits/biofuels — alongside the continuing core operations at India Glycols.

The filing itself does not provide any fresh financial numbers, earnings guidance or valuation metrics for the three businesses, nor does it quantify expected synergies or costs from the restructuring. It also does not specify when exactly the boards will meet to set the Effective Date and Record Date.

What the filing does not tell us

For investors, several key questions remain unanswered by this document:

• Timing: Beyond stating that the Effective Date and Record Date “shall be communicated in due course”, the filing does not give a schedule for when trading in the new entities might begin.
• Post-demerger profiles: The order describes which undertakings move where, but it does not include revenue, profit or asset breakdowns for the Biopharma Undertaking, the Spirits and Biofuel Undertaking, or the Remaining Business.
• Capital structure and listing path: While the share allotment ratios and face value (Rs. 5 per share) are clearly set out, the filing does not discuss listing timelines or potential re-rating scenarios for the resulting companies.

Given that, the 5.0% move after the disclosure likely reflects the market’s positive read-through from procedural progress on a long-flagged restructuring, rather than any new hard financial data in this specific filing.

Bottom line

India Glycols’ latest update confirms that the NCLT-sanctioned demerger of its biopharma and spirits/biofuel businesses is now moving from court approval into the implementation phase. With the certified order in hand and the Appointed Date fixed at 1st April 2026, the next catalysts for the stock will be board decisions on the Effective Date and Record Date, and subsequent clarity on how and when shareholders will see the two resulting companies in their portfolios.